KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) Leases (2019 - 2025)

Novavax has reported Leases over the past 6 years, most recently at $20.3 million for Q4 2025.

  • Quarterly results put Leases at $20.3 million for Q4 2025, down 6.93% from a year ago — trailing twelve months through Dec 2025 was $20.3 million (down 6.93% YoY), and the annual figure for FY2025 was $20.3 million, down 6.93%.
  • Leases for Q4 2025 was $20.3 million at Novavax, down from $21.8 million in the prior quarter.
  • Over the last five years, Leases for NVAX hit a ceiling of $108.5 million in Q3 2022 and a floor of $20.3 million in Q4 2025.
  • Median Leases over the past 4 years was $69.9 million (2022), compared with a mean of $59.7 million.
  • Biggest five-year swings in Leases: plummeted 64.23% in 2023 and later fell 6.93% in 2025.
  • Novavax's Leases stood at $69.9 million in 2022, then tumbled by 64.23% to $25.0 million in 2023, then fell by 12.56% to $21.8 million in 2024, then fell by 6.93% to $20.3 million in 2025.
  • The last three reported values for Leases were $20.3 million (Q4 2025), $21.8 million (Q4 2024), and $25.0 million (Q4 2023) per Business Quant data.